Psychedelic Therapies: Safety and Legality of Psychedelic Compounds
Download PDF
When proper doses of psychedelics are taken, most describe their experiences as “out of body” with a new stream of consciousness. This may be key in the treatment of various psychiatric conditions.
References
Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. May 2019;197:83-102. doi:10.1016/j.pharmthera.2018.11.010
Dominguez-Clave E, Soler J, Elices M, et al. Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res Bull. Sep 2016;126(Pt 1):89-101. doi:10.1016/j.brainresbull.2016.03.002
Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. Mar 2019;49(4):655-663. doi:10.1017/S0033291718001356
Uthaug MV, Davis AK, Haas TF, et al. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol. Mar 2022;36(3):309-320. doi:10.1177/02698811211013583
Lowe H, Toyang N, Steele B, et al. The Therapeutic Potential of Psilocybin. Molecules. May 15 2021;26(10)doi:10.3390/molecules26102948
Richert L, Dyck E. Psychedelic crossings: American mental health and LSD in the 1970s. Med Humanit. Sep 2020;46(3):184-191. doi:10.1136/medhum-2018-011593
Varker T, Watson L, Gibson K, Forbes D, O'Donnell ML. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. J Psychoactive Drugs. Jan-Mar 2021;53(1):85-95. doi:10.1080/02791072.2020.1817639
Passie T, Benzenhofer U. MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s). Drug Test Anal. Jan 2018;10(1):72-80. doi:10.1002/dta.2292
Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry (2023).
Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Curr Neuropharmacol. 2019;17(2):108-128. doi:10.2174/1570159X16666180125095902
Sanches RF, de Lima Osorio F, Dos Santos RG, et al. Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol. Feb 2016;36(1):77-81. doi:10.1097/JCP.0000000000000436
Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. Nov 2022;25(11):1407-1419. doi:10.1038/s41593-022-01177-4
Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Curr Mol Pharmacol. 2019;12(3):184-194. doi:10.2174/1874467211666181010154139
Husain MI, Blumberger DM, Castle DJ, et al. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open. Jul 25 2023;9(4):e134. doi:10.1192/bjo.2023.535
Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. Jul 2016;3(7):619-27. doi:10.1016/S2215-0366(16)30065-7
Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). Feb 2018;235(2):399-408. doi:10.1007/s00213-017-4771-x
Ching THW, Grazioplene R, Bohner C, et al. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front Psychiatry. 2023;14:1178529. doi:10.3389/fpsyt.2023.1178529
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. Nov 2014;28(11):983-92. doi:10.1177/0269881114548296
Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. Jan 2017;43(1):55-60. doi:10.3109/00952990.2016.1170135
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. Mar 2015;29(3):289-99. doi:10.1177/0269881114565144
Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. May 1 2020;177(5):391-410. doi:10.1176/appi.ajp.2019.19010035
Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. Jul 2012;26(7):994-1002. doi:10.1177/0269881112439253
Agin-Liebes G, Nielson EM, Zingman M, et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis. Psychol Addict Behav. Jun 5 2023;doi:10.1037/adb0000935
Traynor JM, Roberts DE, Ross S, Zeifman R, Choi-Kain L. MDMA-Assisted Psychotherapy for Borderline Personality Disorder. Focus (Am Psychiatr Publ). Oct 2022;20(4):358-367. doi:10.1176/appi.focus.20220056
Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. Jun 2021;27(6):1025-1033. doi:10.1038/s41591-021-01336-3
Lear MK, Smith SM, Pilecki B, Stauffer CS, Luoma JB. Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol. Front Psychiatry. 2023;14:1083354. doi:10.3389/fpsyt.2023.1083354
Mitchell JM, Ot'alora GM, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. Sep 14 2023;doi:10.1038/s41591-023-02565-4
Rudnick G, Wall SC. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A. Mar 1 1992;89(5):1817-21. doi:10.1073/pnas.89.5.1817
van Dijken GD, Blom RE, Hene RJ, Boer WH, Consortium N. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant. Sep 2013;28(9):2277-83. doi:10.1093/ndt/gft023
Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. Aug 2008;22(6):603-20. doi:10.1177/0269881108093587
Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol. Mar 2022;36(3):258-272. doi:10.1177/02698811211069100
Johansen PO, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. Mar 2015;29(3):270-9. doi:10.1177/0269881114568039
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
System Update:
Our web site will be offline starting August 17 for major upgrades.
We appreciate your patience as we work to improve your experience.
If you need help during the downtime, please email info@aapp.org.
Learn more.